Showing 1441-1450 of 1644 results for "".
- Fintepla Reduced Seizures in Those with Developmental and Epileptic Encephalopathieshttps://practicalneurology.com/news/fintepla-reduced-seizures-in-those-with-developmental-and-epileptic-encephalopathies/2470519/Results of a meta-analysis published in Epilepsia demonstrated that Fintepla (fenfluramine; UCB, Atlanta, GA) treatment was associated with a reduction in the frequency of generalized tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) in individuals with developmental and epile
- Improvements in Cognition, Alzheimer Disease Biomarkers Linked to Novel Small Molecule Drughttps://practicalneurology.com/news/improvements-in-cognition-alzheimer-disease-biomarkers-linked-to-treatment-with-buntanetap/2470512/Treatment with buntanetap (Annovis Bio, Malvern, PA), an oral molecule with potential therapeutic applications in neurodegenerative conditions such as Parkinson disease (PD) and Alzheimer disease (AD), was associated with significant improvements in cognition and biomarker measures in people with
- Eplontersen Improves Disease State and QoL in People with Hereditary ATTRv-PNhttps://practicalneurology.com/news/eplontersen-improves-disease-state-and-qol-in-people-with-hereditary-attrv-pn/2470305/In the phase 3 clinical trial NEURO-TTRansform (NCT04136184), treatment with eplontersen (AstraZeneca; Cambridge, UK; Ionis Pharmaceuticals, Carslbad, CA), an investigational ligand-conjugated antisense (LICA) medication that inhibits production of the transthyretin (TTR) protein, was associated
- Potential New Biomarker for CNS Demyelination Identifiedhttps://practicalneurology.com/news/potential-new-biomarker-for-cns-demyelination-identified/2470267/Results from a study recently published in JAMA Neurology identified myelin oligodendrocyte glycoprotein (MOG)-associated immunoglobulin A (IgA) in a small number of patients who were double negative for serum aquapo
- At Home Testing of Neurocognitive Function in People with Alzheimer Disease Shows Potential According to Study from Cumulus Neurosciencehttps://practicalneurology.com/news/at-home-testing-of-neurocognitive-function-in-people-with-alzheimer-disease-shows-potential-according-to-study-from-cumulus-neuroscience/2470255/A presentation at the 2023 meeting of the Alzheimer’s Association International Conference (AAIC) demonstrated the potential for at-home sampling of clinical data for patients with early stages of Alzheimer Disease (A
- Full Results from TRAILBLAZER-ALZ 2 Demonstrate Donanemab Effective at Slowing Cognitive and Functional Decline in Early Alzheimer Diseasehttps://practicalneurology.com/news/new-results-from-trailblazer-alz-2-demonstrate-donanemab-effective-at-slowing-cognitive-and-functional-decline-in-early-alzheimer-disease/2470243/The full results of the phase 3 TRAILBLAZER-ALZ 2 (NCT04437511) study were presented at the 2023 meeting of the Alzheimer’s Association International Conference (AAIC), showing that treatment with donanemab (Eli Lilly
- First US County-Level Alzheimer Dementia Assessment Documents Region-Specific Disease Prevalencehttps://practicalneurology.com/news/first-us-county-level-alzheimer-dementia-assessment-documents-region-specific-disease-prevalence/2470240/The first ever county-level Alzheimer dementia assessment in the United States estimated the region-specific burden of Alzheimer disease (AD). These results were presented at the 2023 Alzheimer’s Association Internati
- CRISPR/dCAS9 Shows Promise in Editing APOE ε4 to Treat Late Onset Alzheimer Diseasehttps://practicalneurology.com/news/crisprdcas9-shows-promise-in-editing-apoe-e4-to-treat-late-onset-alzheimer-disease/2470239/Results presented at the 2023 meeting of the Alzheimer’s Association International Conference (AAIC) demonstrate the potential of a novel CRISPR/dCas9-editing strategy to treat late onset Alzheimer disease (LOAD) by t
- Research Shows Potential of Smartphone Applications for Brain Health Assessment in Rural Communitieshttps://practicalneurology.com/news/research-shows-potential-of-smartphone-applications-for-brain-health-assessment-in-rural-communities/2470241/Smartphone applications may be an effective, scalable, low-cost, adaptable strategy for assessing brain health in rural communities, according to research presented at the 2023 meeting of the Alzheimer’s Association I
- Study Evaluates Stigma of High-Frequency Headache/Migraine with Acute Medication Overdose as a Factor of Age, Gender, Employment Status, and Race/Ethnicityhttps://practicalneurology.com/news/study-evaluates-stigma-of-high-frequency-headachemigraine-with-acute-medication-overdose-as-a-factor-of-age-gender-employment-status-and-raceethnicity/2470213/Stigma associated with high-frequency headache/migraine with acute medication overdose (HFM+AMO) is more prevalent in employed, non-Hispanic Black male patients aged 18-49 years, according to a new study presented at the 65